PRESSEPORTAL Presseportal Logo
All Stories
Follow
Subscribe to Stada Arzneimittel

24.04.2001 – 08:24

Stada Arzneimittel

ots Ad hoc-Service: STADA Arzneimittel AG

Bad Vilbel (ots Ad hoc-Service) -

Ad hoc-announcement. The sender is solely
responsible for the contents of this announcement.
STADA: Record results and growth forecast - Conversion of
preferred stock to common stock planned In publishing its results for
the fiscal year 2000 STADA Arzneimittel AG presents its fifth record
year in a row. The earnings before interest, taxes and depreciation
(EBITDA) for the Group reached DM 106.1 million, an increase of +43%
compared to the previous years figure of DM 74.0 million. After
adjusting for one-time extraordinary expenses of DM 6.9 million in
connection with the capital increase, and with the floating of a
warrant issue in May of 2000, the consolidated net earnings come to
DM 36.0 million - an increase of +63% over the figure of DM 22.1
million for the previous year. Sales increased by +32% to DM 913.7
million (previous year: DM 692.9 million). Twenty-four percent-points
of the growth in sales can be attributed to organic growth, and eight
percent- points to acquisitions. The Executive Board expects the
dynamic growth to continue in the current fiscal year 2001, with
sales of DM 1.1 billion which will clearly top the billion threshold
for sales. The EBITDA is also expected to increase by double-digit
percentages. The trend in STADAs sales in the first three months
confirm this prognosis. The sales growth of about +16% in the first
quarter of 2001 falls within the planning range, and makes the
expected sales increase of +20% for the entire fiscal year 2001
appear realistic. (The final results for the 1st quarter of 2001 will
be published on May 11, 2001.) At the shareholders meeting on June
19, 2001 the Executive Board and the Supervisory Board will propose
to the shareholders that the preferred stock be converted to
registered common stock. That is in pursuit of the goal of increasing
the liquidity of STADAs stock by concentrating on one category of
shares.
For further information please contact: STADA Arzneimittel AG /
Corporate Communication / 61118 Bad Vilbel Tel.: +49(0) 6101 603-113
/ Fax: +49(0) 6101 603-506 / E-Mail: communication@stada.de
Or visit us on the Internet at www.stada.de.
WKN: 725180; Index: SDax Listed: Amtlicher Handel in Frankfurt
(SMAX) und Düsseldorf; Freiverkehr in Berlin, Hamburg, München und
Stuttgart
End
Internet: http://recherche.newsaktuell.de

Original content of: Stada Arzneimittel, transmitted by news aktuell